368 related articles for article (PubMed ID: 30220105)
21. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
22. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
23. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma.
Theisen ER; Gajiwala S; Bearss J; Sorna V; Sharma S; Janat-Amsbury M
BMC Cancer; 2014 Oct; 14():752. PubMed ID: 25300887
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1α-dependent pathway.
Saccà CD; Gorini F; Ambrosio S; Amente S; Faicchia D; Matarese G; Lania L; Majello B
Biochim Biophys Acta Gene Regul Mech; 2019 May; 1862(5):535-546. PubMed ID: 30951900
[TBL] [Abstract][Full Text] [Related]
26. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
He Y; Zhao Y; Wang L; Bohrer LR; Pan Y; Wang L; Huang H
Oncogene; 2018 Jan; 37(4):534-543. PubMed ID: 28991226
[TBL] [Abstract][Full Text] [Related]
27. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
28. Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production.
Fan J; Zhang X; Wang S; Chen W; Li Y; Zeng X; Wang Y; Luan J; Li L; Wang Z; Sun X; Shen B; Ju D
Cell Death Dis; 2019 Aug; 10(9):626. PubMed ID: 31427566
[TBL] [Abstract][Full Text] [Related]
29. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
31. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Wang Y; Zhu Y; Wang Q; Hu H; Li Z; Wang D; Zhang W; Qi B; Ye J; Wu H; Jiang H; Liu L; Yang J; Cheng J
Cancer Lett; 2016 Apr; 374(1):12-21. PubMed ID: 26872725
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
33. Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.
Cuyàs E; Gumuzio J; Lozano-Sánchez J; Carreras D; Verdura S; Llorach-Parés L; Sanchez-Martinez M; Selga E; Pérez GJ; Scornik FS; Brugada R; Bosch-Barrera J; Segura-Carretero A; Martin ÁG; Encinar JA; Menendez JA
Nutrients; 2019 Jul; 11(7):. PubMed ID: 31331073
[TBL] [Abstract][Full Text] [Related]
34. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
[TBL] [Abstract][Full Text] [Related]
35. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
36. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
[TBL] [Abstract][Full Text] [Related]
37. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
Schulte JH; Lim S; Schramm A; Friedrichs N; Koster J; Versteeg R; Ora I; Pajtler K; Klein-Hitpass L; Kuhfittig-Kulle S; Metzger E; Schüle R; Eggert A; Buettner R; Kirfel J
Cancer Res; 2009 Mar; 69(5):2065-71. PubMed ID: 19223552
[TBL] [Abstract][Full Text] [Related]
38. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma.
Tang Q; Li W; Zheng X; Ren L; Liu J; Li S; Wang J; Du G
Signal Transduct Target Ther; 2020 Dec; 5(1):279. PubMed ID: 33262323
[TBL] [Abstract][Full Text] [Related]
39. LSD1 Histone Demethylase Assays and Inhibition.
Hayward D; Cole PA
Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
